Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

Cuorips, a Japan-based cell therapy developer spun out of Osaka University, has secured ¥1.6bn ($14.7m) from a consortium featuring respective vehicles for Osaka and Kyoto universities. Handai Venture NVCC I and Kyodai Venture NVCC II, managed by Nippon Venture Capital on behalf of Osaka and Kyoto respectively, were joined in the round by regenerative medicine…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.